145 related articles for article (PubMed ID: 38277483)
1. Biomimetic Nanomedicine Targeting Orchestrated Metabolism Coupled with Regulatory Factors to Disrupt the Metabolic Plasticity of Breast Cancer.
Meng L; Yang J; Gao Y; Cao Q; Jiang S; Xiao Y; Wang H; Liu W; Yuan A; Li Y; Huang H
ACS Nano; 2024 Feb; 18(5):4360-4375. PubMed ID: 38277483
[TBL] [Abstract][Full Text] [Related]
2. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α.
Faubert B; Vincent EE; Griss T; Samborska B; Izreig S; Svensson RU; Mamer OA; Avizonis D; Shackelford DB; Shaw RJ; Jones RG
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2554-9. PubMed ID: 24550282
[TBL] [Abstract][Full Text] [Related]
3. Glutamine metabolism in breast cancer and possible therapeutic targets.
Li S; Zeng H; Fan J; Wang F; Xu C; Li Y; Tu J; Nephew KP; Long X
Biochem Pharmacol; 2023 Apr; 210():115464. PubMed ID: 36849062
[TBL] [Abstract][Full Text] [Related]
4. Metabolic intervention liposome for targeting glutamine-addiction of breast cancer.
Wu M; Wang Q; Chen S; Zhou Z; Li J; Sun H; Liu J; Wang G; Zhou F; Sun M
J Control Release; 2022 Oct; 350():1-10. PubMed ID: 35907591
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
Magaway C; Kim E; Jacinto E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
[TBL] [Abstract][Full Text] [Related]
6. Glutamine metabolism links growth factor signaling to the regulation of autophagy.
van der Vos KE; Coffer PJ
Autophagy; 2012 Dec; 8(12):1862-4. PubMed ID: 22996802
[TBL] [Abstract][Full Text] [Related]
7. Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells.
Sudhagar S; Sathya S; Lakshmi BS
Br J Cancer; 2011 Sep; 105(7):953-60. PubMed ID: 21897387
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.
Zhou L; Zhao Y; Pan LC; Wang J; Shi XJ; Du GS; He Q
World J Gastroenterol; 2022 Aug; 28(32):4600-4619. PubMed ID: 36157928
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.
Badoiu SC; Greabu M; Miricescu D; Stanescu-Spinu II; Ilinca R; Balan DG; Balcangiu-Stroescu AE; Mihai DA; Vacaroiu IA; Stefani C; Jinga V
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176098
[TBL] [Abstract][Full Text] [Related]
10. AMPK Inhibits ULK1-Dependent Autophagosome Formation and Lysosomal Acidification via Distinct Mechanisms.
Nwadike C; Williamson LE; Gallagher LE; Guan JL; Chan EYW
Mol Cell Biol; 2018 May; 38(10):. PubMed ID: 29507183
[TBL] [Abstract][Full Text] [Related]
11. Analyzing the impact of autotrophic and heterotrophic metabolism on the nutrient regulation of TOR.
Mallén-Ponce MJ; Pérez-Pérez ME; Crespo JL
New Phytol; 2022 Nov; 236(4):1261-1266. PubMed ID: 36052700
[TBL] [Abstract][Full Text] [Related]
12. Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mTOR).
Foster DA; Salloum D; Menon D; Frias MA
J Biol Chem; 2014 Aug; 289(33):22583-22588. PubMed ID: 24990952
[TBL] [Abstract][Full Text] [Related]
13. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.
De Santis MC; Gozzelino L; Margaria JP; Costamagna A; Ratto E; Gulluni F; Di Gregorio E; Mina E; Lorito N; Bacci M; Lattanzio R; Sala G; Cappello P; Novelli F; Giovannetti E; Vicentini C; Andreani S; Delfino P; Corbo V; Scarpa A; Porporato PE; Morandi A; Hirsch E; Martini M
Gut; 2023 Feb; 72(2):360-371. PubMed ID: 35623884
[TBL] [Abstract][Full Text] [Related]
15. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation.
Peng T; Golub TR; Sabatini DM
Mol Cell Biol; 2002 Aug; 22(15):5575-84. PubMed ID: 12101249
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial phosphoenolpyruvate carboxykinase promotes tumor growth in estrogen receptor-positive breast cancer via regulation of the mTOR pathway.
Hsu HP; Chu PY; Chang TM; Huang KW; Hung WC; Jiang SS; Lin HY; Tsai HJ
Cancer Med; 2023 Jan; 12(2):1588-1601. PubMed ID: 35757841
[TBL] [Abstract][Full Text] [Related]
17. Bone metastatic breast cancer cells display downregulation of PKC-ζ with enhanced glutamine metabolism.
Tandon M; Othman AH; Winogradzki M; Pratap J
Gene; 2021 Apr; 775():145419. PubMed ID: 33444686
[TBL] [Abstract][Full Text] [Related]
18. Hopefully devoted to Q: targeting glutamine addiction in cancer.
Still ER; Yuneva MO
Br J Cancer; 2017 May; 116(11):1375-1381. PubMed ID: 28441384
[TBL] [Abstract][Full Text] [Related]
19. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.
Shajahan-Haq AN; Cook KL; Schwartz-Roberts JL; Eltayeb AE; Demas DM; Warri AM; Facey CO; Hilakivi-Clarke LA; Clarke R
Mol Cancer; 2014 Oct; 13():239. PubMed ID: 25339305
[TBL] [Abstract][Full Text] [Related]
20. Amino acid management in cancer.
Tsun ZY; Possemato R
Semin Cell Dev Biol; 2015 Jul; 43():22-32. PubMed ID: 26277542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
